This phase I trial studies how well iodine I 124 (124I) positron emission tomography (PET)/computed tomography (CT) scan works in diagnosing the amount of iodine I-131 (131I) radioactive iodine uptake in patients with thyroid cancer that has spread to other places in the body (metastatic). 131I is a standard of care treatment used to find and destroy thyroid cancer cells that have spread to other places in the body. 124I is a different radioactive form of iodine that may be able to accurately measure the amount of radioactive iodine uptake in thyroid cancer. A PET/CT scan may allow doctors to determine how much radiation each metastatic lesion will receive. 124I PET/CT scan may help to predict which patients may not respond to 131I treatments and avoid exposing those patients to unnecessary radiation and custom tailor the 131I dose to destroy the metastatic lesions in rest of the patients.
Additional locations may be listed on ClinicalTrials.gov for NCT03647358.
Locations matching your search criteria
United States
New York
New York
Memorial Sloan Kettering Cancer CenterStatus: Active
Contact: Ravinder Kaur Grewal
Phone: 212-639-2872
NYP/Weill Cornell Medical CenterStatus: Approved
Contact: Joseph Reginald Osborne
Phone: 212-746-6000
PRIMARY OBJECTIVES:
I. To establish a clinically practical 124I PET imaging paradigm to select patients who may benefit from high dose radioiodine therapy.
II. To correlate 124I PET lesion dose estimation with individual lesion response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients undergoing high dose 131I therapy.
III. Determine the biological basis of radioiodine incorporation by exploring the genomic landscape and the expression of key iodine metabolism and MAPK transcriptional output genes in metastatic lesions with high and low 124I PET lesional uptake in a small sub-set of 20 patients, which will be enrolled onto this protocol and also Institutional Review Board (IRB) protocol 13-157 (principal investigator [PI]: Alan Ho, Doctor of Medicine [MD]).
IV. To determine the accuracy of the therapeutic dose prescriptions by 124I PET imaging during 131I high-dose therapy.
OUTLINE:
Patients receive iodine I 124 orally (PO) on day 2 or 3 of lesional dosimetry protocol and then undergo up to 4 PET/CT scans at 24, 48, 72, and 120 hours post-iodine I 124 oral dose.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorRavinder Kaur Grewal
